|
QURE | Uniqure N.v. |
|
|
QURE | Uniqure N.v. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.22 |
| Leverage | 74.25% |
| Market Cap | $ 1.0B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -234.0m |
| Margin | -778.35% |
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.